缺血性卒中合并房颤与动脉粥样硬化:抗栓联合治疗随机试验
这项多中心开放标签随机试验纳入316例缺血性卒中或TIA合并非瓣膜性房颤及动脉粥样硬化性心血管病患者,比较抗凝联合抗血小板与抗凝单药治疗。
要点
- 联合治疗组大出血及临床相关非大出血风险显著升高(19.5% vs 8.6%,HR 2.42)。
- 因无效提前终止,不支持常规联合抗血小板用于此类患者。
核心结论
- 在缺血性卒中或TIA合并非瓣膜性房颤及动脉粥样硬化性心血管病患者中,抗凝联合抗血小板较抗凝单药无净临床获益,且出血风险更高。
研究设计与样本
- 多中心、开放标签随机临床试验,在日本41个中心开展,2016年11月至2025年3月入组。
- 共随机316例,联合治疗组159例,单药组157例;平均年龄77.2岁(SD 7.4),女性90例(28.5%)。
- 纳入标准:缺血性卒中或TIA起病8至360天内,合并非瓣膜性房颤,且至少1项动脉粥样硬化性心血管病表现。
主要发现
- 试验因无效于2023年7月18日提前终止。
临床怎么用
- 对于缺血性卒中或TIA合并非瓣膜性房颤及动脉粥样硬化性心血管病患者,不推荐常规在抗凝基础上加用抗血小板药物。
- 临床决策应权衡缺血与出血风险,优先考虑抗凝单药治疗。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(316例),事件数有限,统计效能不足。
- 试验因无效提前终止,结果解释需谨慎。
- 仅在日本人群中进行,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with ischemic stroke and concurrent nonvalvular atrial fibrillation and atherosclerotic cardiovascular disease are at an elevated risk of recurrent ischemic events. Although combined anticoagulant and antiplatelet therapy may reduce ischemic risk, it also increases bleeding, and the optimal antithrombotic strategy remains uncertain. OBJECTIVE: To determine whether adding an antiplatelet agent to anticoagulant therapy influences the net clinical benefit in patients with ischemic stroke or transient ischemic attack and concurrent nonvalvular atrial fibrillation and atherosclerotic cardiovascular disease. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label randomized clinical trial was conducted at 41 sites across Japan from November 2016 to March 2025. Eligible patients had an ischemic stroke or transient ischemic attack within 8 to 360 days of onset, nonvalvular atrial fibrillation, and at least 1 manifestation of atherosclerotic cardiovascular disease (carotid or intracranial artery stenosis, noncardioembolic stroke, ischemic heart disease, or peripheral artery disease). Data were analyzed from April 16, 2024, to October 14, 2024. INTERVENTIONS: Patients were randomized to receive combination therapy (anticoagulant plus antiplatelet) or anticoagulant monotherapy. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of ischemic cardiovascular events and major bleeding within 2 years. Secondary outcomes included ischemic cardiovascular events; safety outcomes included major and clinically relevant nonmajor bleeding. RESULTS: In total, 316 patients were randomized to combination therapy (n = 159) or monotherapy (n = 157) (mean [SD] age, 77.2 [7.4] years; 90 female patients [28.5%]). The trial was terminated on July 18, 2023, after an interim analysis for futility. The cumulative incidence of the primary outcome was 17.8% in the combination therapy group and 19.6% in the monotherapy group (hazard ratio [HR], 0.91; 95% CI, 0.53-1.55; P = .64). Ischemic cardiovascular events occurred in 11.1% and 14.2% (HR, 0.76; 95% CI, 0.39-1.48; P = .41), and major and clinically relevant nonmajor bleeding occurred in 19.5% and 8.6% (HR, 2.42; 95% CI, 1.23-4.76; P = .008) of combination therapy and monotherapy groups, respectively. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, in patients with ischemic stroke or transient ischemic attack and concurrent nonvalvular atrial fibrillation and atherosclerotic cardiovascular disease, adding an antiplatelet agent to anticoagulant therapy provided no net clinical benefit over anticoagulant monotherapy, with higher bleeding risk. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03062319.
引用
- Okazaki S, Tanaka K, Yazawa Y, et al. Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis: A Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 41051787. doi:10.1001/jamaneurol.2025.3662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。